HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BBR 3576

has antineoplastic activity; structure in first source

Also Known As:

BBR-3576; BBR3576

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - BBR 3576: 1
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - BBR 3576: 1

Experts

1.	Barbieri, Paola: 1 article (01/2004)
2.	Bernareggi, Alberto: 1 article (01/2004)
3.	Camboni, Maria G: 1 article (01/2004)
4.	Kutz, Klaus: 1 article (01/2004)
5.	Licht, Thomas: 1 article (01/2004)
6.	Mross, Klaus: 1 article (01/2004)
7.	Richly, Heike: 1 article (01/2004)
8.	Scheulen, Max E: 1 article (01/2004)
9.	Stern, Angelika C: 1 article (01/2004)
10.	Unger, Clemens: 1 article (01/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2004 - "Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)."
2.	Cardiotoxicity 01/01/2004 - "BBR 3576 is a novel aza-anthrapyrazole with limited potential for cardiotoxicity in preclinical models. "

Related Drugs and Biologics

1.	anthrapyrazole